AFWM
NBIX icon

Abich Financial Wealth Management’s Neurocrine Biosciences NBIX Stock Holding History

Abich Financial Wealth Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$90.1K Buy
+642
New +$87K 0.03% 248
2024
Q3 		– Sell
-29
Closed -$3.99K – 694
2024
Q2 		$3.99K Buy
+29
New +$3.98K ﹤0.01% 369

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Abich Financial Wealth Management's NBIX Position: Q3 2025 in Review

Abich Financial Wealth Management opened a new position in Neurocrine Biosciences (NBIX) in Q3 2025: 642 shares worth $90.1K. The stake represents 0.03% of the portfolio and ranks #248 among its holdings. This is a return to the name: Abich Financial Wealth Management previously reported a position in NBIX as recently as Q2 2024.

Abich Financial Wealth Management first reported a position in NBIX in Q2 2024 and has held it in 2 quarters since. 650 funds tracked by Wall St. Rank hold NBIX as of Q3 2025.

  • Abich Financial Wealth Management held 642 shares of Neurocrine Biosciences worth $90.1K as of Q3 2025.
  • Neurocrine Biosciences was a new Abich Financial Wealth Management position in Q3 2025.
  • Neurocrine Biosciences made up 0.03% of Abich Financial Wealth Management's portfolio in Q3 2025, its #248 holding.
  • Abich Financial Wealth Management first reported a position in Neurocrine Biosciences in Q2 2024 and has held it in 2 quarters since.
  • 650 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2025.

Based on Abich Financial Wealth Management's 13F filing for Q3 2025, filed 6 Nov 2025.